BioTrends Announces Newly Expanded Oncology Division to Focus on Launch Metrics of Bristol-Myers Squibb’s Yervoy, Roche an

EXTON, Pa.--(BUSINESS WIRE)-- The Oncology marketplace is going through a paradigm shift with new product launches and competitive promotion vying for patient treatment share. These new marketing reports written by Oncology experts will provide essential insights into the market dynamics.

LaunchTrends® provides insights on uptake of new products and the Impact of new products on market dynamics. LaunchTrends are syndicated report series that track the trial, adoption and usage of new products during the initial launch year. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics.

  • LaunchTrends®: Melanoma (Yervoy & Zelboraf) There has been limited advances in the treatment of melanoma over the last decade. A major catalyst for change is now here with the launch of Bristol-Myers Squibb’s Yervoy, a monoclonal antibody that may stimulate the immune system to fight cancer and Genentech’s Zelboraf, a first-in-class personalized treatment that works on patients with a BRAFV600E mutation.
  • LaunchTrends®: Xalkori (crizotinib) Personalized medicine continues to be driver of change in the Oncology marketplace, with the launch of Pfizer’s Xalkori a targeted therapy which has recently been approved for advanced Non-Small-Cell Lung Cancer (NSCLC) in patients with a specific biomarker (anaplastatic lymphoma kinase [ALK]) positive).
  • LaunchTrends®: Zytiga (abiraterone acetate) The highest unmet need in Prostate cancer market is effective treatments for the advanced form of the disease. Johnson & Johnson’s Zytiga has been approved for patients with docetaxel-pretreated metastatic castration-resistant prostate cancer. Provenge was approved in 2010 for first-line asymptomatic metastatic castration-resistant prostate cancer.

TreatmentTrends® analyzes physicians attitudes, perceptions and self-reported prescribing behavior. TreatmentTrends are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, physician attitudes and perceptions, and current and projected use of various products.

  • TreatmentTrends®: Multiple Myeloma – This market is very competitive with widespread use of Celgene’s Revlimid, Celgene’s Thalomid and Millennium’s Velcade. As new clinical data is being presented it is creating paradigm shifts on how this disease state is being managed.

Dan Winkelman a Therapeutic Class Director in Oncology at BioTrends stated “The medical advances of the last decade are starting to bear fruit with some exciting products launches in markets with high unmet needs. We believe our clients will derive significant benefit from the new BioTrends report offerings which provide more in-depth insights.”

Based on customer feedback in the 2011-2012 timeframe BioTrends will be covering six key areas of cancer that are expected to have significant change. In the solid-tumor indications, BioTrends is fielding research on: Breast Cancer, Prostate Cancer, Malignant Melanoma and Non-Small-Cell Lung Cancer. In hematology-oncology initial coverage will cover Chronic Myeloid Leukemia and Multiple Myeloma.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information on BioTrends Oncology products, contact:

Andrew Merron ([email protected]) and Dan Winkelman ([email protected]), Therapeutic Class Directors, Oncology.



CONTACT:

BioTrends Research Group, LLC
Elisa Picardi Ferrante, +1 610-321-9432
[email protected]
or
Decision Resources Group
Christopher Comfort, +1 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.